{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:41:54Z","timestamp":1791042114309,"version":"4.1.0"},"reference-count":273,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009793","name":"Chapman University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R41AI164997-01A1"],"award-info":[{"award-number":["1R41AI164997-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL147311-S1"],"award-info":[{"award-number":["HL147311-S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG062840"],"award-info":[{"award-number":["R01AG062840"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG072896"],"award-info":[{"award-number":["R01AG072896"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.addr.2023.114968","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T17:13:23Z","timestamp":1687367603000},"page":"114968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["siRNA drug delivery across the blood\u2013brain barrier in Alzheimer's disease"],"prefix":"10.1016","volume":"199","author":[{"given":"Muhammad","family":"Imran Sajid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Sultan Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Anis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourina","family":"Nasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachita K.","family":"Sumbria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya M.","family":"Nauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.114968_b0005","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/CIA.S105769","article-title":"Genes associated with Alzheimer\u2019s disease: an overview and current status","volume":"11","author":"Giri","year":"2016","journal-title":"Clinical Interventions in Aging"},{"key":"10.1016\/j.addr.2023.114968_b0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-secretase BACE1 in Alzheimer\u2019s disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biological psychiatry"},{"key":"10.1016\/j.addr.2023.114968_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-7-7","article-title":"Recent developments in Alzheimer's disease therapeutics","volume":"7","author":"Rafii","year":"2009","journal-title":"BMC medicine"},{"key":"10.1016\/j.addr.2023.114968_b0020","unstructured":"WHO, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia, 2021."},{"key":"10.1016\/j.addr.2023.114968_b0025","unstructured":"M. Monica Moore, M. D\u00edaz-Santos, K. Vossel, Alzheimer\u2019s Association 2021 Facts and Figures Report."},{"key":"10.1016\/j.addr.2023.114968_b0030","unstructured":"ALZ.org, https:\/\/www.alz.org\/alzheimers-dementia\/facts-figures, 2021."},{"key":"10.1016\/j.addr.2023.114968_b0035","unstructured":"A.s. Association, Alzheimer\u2019s Association. 2021 Alzheimer\u2019s Disease Facts and Figures. Alzheimer's Dement, 17 (2021)."},{"key":"10.1016\/j.addr.2023.114968_b0040","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-019-0101-y","article-title":"The proteostasis network and its decline in ageing","volume":"20","author":"Hipp","year":"2019","journal-title":"Nature reviews Molecular cell biology"},{"key":"10.1016\/j.addr.2023.114968_b0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/nar\/gkh208","article-title":"Targeting Alzheimer\u2019s disease genes with RNA interference: An efficient strategy for silencing mutant alleles","volume":"32","author":"Miller","year":"2004","journal-title":"Nucleic acids research"},{"key":"10.1016\/j.addr.2023.114968_b0050","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/CIA.S105769","article-title":"Genes associated with Alzheimer\u2019s disease: An overview and current status","volume":"11","author":"Giri","year":"2016","journal-title":"Clinical interventions in aging"},{"key":"10.1016\/j.addr.2023.114968_b0055","article-title":"Current druggable targets for therapeutic control of Alzheimer's disease","volume":"106549","author":"Gupta","year":"2021","journal-title":"Contemporary Clinical Trials"},{"key":"10.1016\/j.addr.2023.114968_b0060","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: An update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.114968_b0065","article-title":"Omics sciences for systems biology in alzheimer\u2019s disease: State-of-the-art of the evidence","volume":"101346","author":"Hampel","year":"2021","journal-title":"Ageing Research Reviews"},{"key":"10.1016\/j.addr.2023.114968_b0070","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fnins.2019.00430","article-title":"Amyloid beta and microRNAs in Alzheimer\u2019s disease","volume":"13","author":"Amakiri","year":"2019","journal-title":"Frontiers in neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0075","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.3233\/JAD-190232","article-title":"Can healthy diets, regular exercise, and better lifestyle delay the progression of dementia in elderly individuals?","volume":"72","author":"George","year":"2019","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/j.addr.2023.114968_b0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-2627-5_1","article-title":"Alzheimer\u2019s as a systems-level disease involving the interplay of multiple cellular networks","author":"Castrillo","year":"2016","journal-title":"Systems Biology of Alzheimer's Disease"},{"key":"10.1016\/j.addr.2023.114968_b0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mam.2015.05.005","article-title":"Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits?","volume":"43","author":"Rosenberg","year":"2015","journal-title":"Molecular aspects of medicine"},{"key":"10.1016\/j.addr.2023.114968_b0090","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awad005","article-title":"Anti-amyloid antibody therapies in Alzheimer's disease","author":"Perneczky","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.addr.2023.114968_b0095","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nn1531","article-title":"Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model","volume":"8","author":"Singer","year":"2005","journal-title":"Nature neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0100","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1021\/acs.molpharmaceut.0c01239","article-title":"siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses","volume":"18","author":"Sajid","year":"2021","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.addr.2023.114968_b0105","first-page":"1","article-title":"Recent advances on drug development and emerging therapeutic agents for Alzheimer\u2019s disease","author":"Athar","year":"2021","journal-title":"Molecular Biology Reports"},{"key":"10.1016\/j.addr.2023.114968_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.01.003","article-title":"Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases","author":"Mishra","year":"2022","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.addr.2023.114968_b0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cortex.2015.07.032","article-title":"Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?","volume":"73","author":"Dekker","year":"2015","journal-title":"Cortex"},{"key":"10.1016\/j.addr.2023.114968_b0120","doi-asserted-by":"crossref","unstructured":"J.D. Stefaniak, L. Su, E. Mak, N. Sheikh\u2010Bahaei, K. Wells, K. Ritchie, A. Waldman, C.W. Ritchie, J.T. O'brien, Cerebral small vessel disease in middle age and genetic predisposition to late\u2010onset Alzheimer's disease, Alzheimer's & Dementia, 14 (2018) 253-258.","DOI":"10.1016\/j.jalz.2017.08.017"},{"key":"10.1016\/j.addr.2023.114968_b0125","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3389\/fnagi.2020.587989","article-title":"Differential profile of systemic extracellular vesicles from sporadic and familial Alzheimer\u2019s disease leads to neuroglial and endothelial cell degeneration","volume":"12","author":"Villar-Vesga","year":"2020","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semcdb.2019.05.014","article-title":"CRISPR\/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases","volume":"96","author":"Rahman","year":"2019","journal-title":"Seminars in Cell & Developmental Biology"},{"key":"10.1016\/j.addr.2023.114968_b0135","doi-asserted-by":"crossref","first-page":"105303","DOI":"10.1016\/j.nbd.2021.105303","article-title":"INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque-associated microglia","volume":"153","author":"Tsai","year":"2021","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.addr.2023.114968_b0140","doi-asserted-by":"crossref","first-page":"101818","DOI":"10.1016\/j.pneurobio.2020.101818","article-title":"PLA2G4E, a candidate gene for resilience in Alzheime\u0155s disease and a new target for dementia treatment","volume":"191","author":"P\u00e9rez-Gonz\u00e1lez","year":"2020","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.addr.2023.114968_b0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semcdb.2019.05.014","article-title":"CRISPR\/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases","author":"Rahman","year":"2019","journal-title":"Seminars in cell & developmental biology, Elsevier"},{"key":"10.1016\/j.addr.2023.114968_b0150","doi-asserted-by":"crossref","first-page":"101818","DOI":"10.1016\/j.pneurobio.2020.101818","article-title":"PLA2G4E, a candidate gene for resilience in Alzheimer s disease and a new target for dementia treatment","volume":"191","author":"P\u00e9rez-Gonz\u00e1lez","year":"2020","journal-title":"Progress in neurobiology"},{"key":"10.1016\/j.addr.2023.114968_b0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0160","article-title":"Disrupted Ubiquitin Proteasome System Underlying Tau Accumulation in Alzheimer\u2019s Disease","author":"Weng","year":"2020","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.addr.2023.114968_b0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0896-6273(92)90117-V","article-title":"Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms","volume":"8","author":"Goedert","year":"1992","journal-title":"Neuron"},{"key":"10.1016\/j.addr.2023.114968_b0170","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5483\/BMBRep.2016.49.8.084","article-title":"Tau mis-splicing in the pathogenesis of neurodegenerative disorders","volume":"49","author":"Park","year":"2016","journal-title":"BMB reports"},{"key":"10.1016\/j.addr.2023.114968_b0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"key":"10.1016\/j.addr.2023.114968_b0180","article-title":"Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer's disease and other tauopathies","volume":"113756","author":"Annadurai","year":"2021","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.addr.2023.114968_b0185","first-page":"815","article-title":"Tauopathies: Classification, clinical features, and genetics, Movement Disorders","author":"Josephs","year":"2015","journal-title":"Elsevier"},{"key":"10.1016\/j.addr.2023.114968_b0190","series-title":"Proteostasis and Disease : From Basic Mechanisms to Clinics","first-page":"177","article-title":"Altered Proteostasis in Neurodegenerative Tauopathies","author":"Papanikolopoulou","year":"2020"},{"key":"10.1016\/j.addr.2023.114968_b0195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-030-38266-7_7","article-title":"Altered proteostasis in neurodegenerative tauopathies","author":"Papanikolopoulou","year":"2020","journal-title":"Proteostasis and Disease"},{"key":"10.1016\/j.addr.2023.114968_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03509-0","article-title":"A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers","volume":"9","author":"Thibaudeau","year":"2018","journal-title":"Nature communications"},{"key":"10.1016\/j.addr.2023.114968_b0205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane","year":"2018","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.addr.2023.114968_b0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/nan.12197","article-title":"Invited review: Prion-like transmission and spreading of tau pathology","volume":"41","author":"Clavaguera","year":"2015","journal-title":"Neuropathology and applied neurobiology"},{"key":"10.1016\/j.addr.2023.114968_b0215","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1111\/ejn.12229","article-title":"Spreading of tau pathology in A lzheimer's disease by cell-to-cell transmission","volume":"37","author":"Mohamed","year":"2013","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0220","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3233\/JAD-170048","article-title":"Tau oligomers in sera of patients with Alzheimer\u2019s disease and aged controls","volume":"58","author":"Kolarova","year":"2017","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/j.addr.2023.114968_b0225","doi-asserted-by":"crossref","first-page":"14234","DOI":"10.1523\/JNEUROSCI.1523-15.2015","article-title":"Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells","volume":"35","author":"Usenovic","year":"2015","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0230","doi-asserted-by":"crossref","first-page":"15317","DOI":"10.1074\/jbc.M110.209296","article-title":"Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles","volume":"286","author":"Guo","year":"2011","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.addr.2023.114968_b0235","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1074\/jbc.M112.394528","article-title":"Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons","volume":"288","author":"Wu","year":"2013","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.addr.2023.114968_b0240","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ncb1901","article-title":"Transmission and spreading of tauopathy in transgenic mouse brain","volume":"11","author":"Clavaguera","year":"2009","journal-title":"Nature cell biology"},{"key":"10.1016\/j.addr.2023.114968_b0245","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.tins.2016.02.002","article-title":"The autophagy\u2013lysosomal pathway in neurodegeneration: A TFEB perspective","volume":"39","author":"Martini-Stoica","year":"2016","journal-title":"Trends in neurosciences"},{"key":"10.1016\/j.addr.2023.114968_b0250","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/j.addr.2023.114968_b0255","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.tins.2019.02.007","article-title":"Neuroimmune crosstalk through extracellular vesicles in health and disease","volume":"42","author":"Delpech","year":"2019","journal-title":"Trends in neurosciences"},{"key":"10.1016\/j.addr.2023.114968_b0260","article-title":"Tau Internalization: A Complex Step in Tau Propagation","volume":"101272","author":"Zhao","year":"2021","journal-title":"Ageing Research Reviews"},{"key":"10.1016\/j.addr.2023.114968_b0265","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12031-018-1174-3","article-title":"Tau protein squired by molecular chaperones during Alzheimer\u2019s disease","volume":"66","author":"Gorantla","year":"2018","journal-title":"Journal of Molecular Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.freeradbiomed.2017.08.024","article-title":"Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome","volume":"114","author":"Zis","year":"2018","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.addr.2023.114968_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-015-1449-5","article-title":"Analyzing dendritic spine pathology in Alzheimer\u2019s disease: problems and opportunities","volume":"130","author":"Dorostkar","year":"2015","journal-title":"Acta neuropathologica"},{"key":"10.1016\/j.addr.2023.114968_b0280","article-title":"Is \u03b3-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?","volume":"100489","author":"Checler","year":"2021","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.addr.2023.114968_b0285","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.febslet.2013.05.010","article-title":"The amyloid precursor protein: a biochemical enigma in brain development, function and disease","volume":"587","author":"Nalivaeva","year":"2013","journal-title":"FEBS letters"},{"key":"10.1016\/j.addr.2023.114968_b0290","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.redox.2017.10.014","article-title":"Oxidative stress and the amyloid beta peptide in Alzheimer\u2019s disease","volume":"14","author":"Cheignon","year":"2018","journal-title":"Redox biology"},{"key":"10.1016\/j.addr.2023.114968_b0295","doi-asserted-by":"crossref","first-page":"14934","DOI":"10.1073\/pnas.93.25.14934","article-title":"ZnT-3, a putative transporter of zinc into synaptic vesicles","volume":"93","author":"Palmiter","year":"1996","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.addr.2023.114968_b0300","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1074\/jbc.M309730200","article-title":"Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain","volume":"279","author":"Lee","year":"2004","journal-title":"Journal of biological chemistry"},{"key":"10.1016\/j.addr.2023.114968_b0305","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ange.201508597","article-title":"Free superoxide is an intermediate in the production of H2O2 by copper (I)-A\u03b2 peptide and O2","volume":"128","author":"Reybier","year":"2016","journal-title":"Angewandte Chemie"},{"key":"10.1016\/j.addr.2023.114968_b0310","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.neuint.2012.12.005","article-title":"Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain","volume":"62","author":"Guo","year":"2013","journal-title":"Neurochemistry international"},{"key":"10.1016\/j.addr.2023.114968_b0315","article-title":"NMDA and AMPA receptors dysregulation in Alzheimer's disease","volume":"174310","author":"Babaei","year":"2021","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.addr.2023.114968_b0320","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0269881118754680","article-title":"Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications","volume":"32","author":"Olloquequi","year":"2018","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.addr.2023.114968_b0325","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons","volume":"57","author":"Rajmohan","year":"2017","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/j.addr.2023.114968_b0330","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ebiom.2017.05.012","article-title":"Local somatodendritic translation and hyperphosphorylation of tau protein triggered by AMPA and NMDA receptor stimulation","volume":"20","author":"Kobayashi","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2023.114968_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.it.2020.07.005","article-title":"Immunological features of non-neuronal brain cells: implications for Alzheimer\u2019s disease immunotherapy","author":"Castellani","year":"2020","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.addr.2023.114968_b0340","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41586-019-1895-7","article-title":"Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer\u2019s disease","volume":"577","author":"Gate","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114968_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-020-00688-1","article-title":"Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer\u2019s disease mouse model with suppression of glymphatic clearance","volume":"12","author":"Feng","year":"2020","journal-title":"Alzheimer's research & therapy"},{"key":"10.1016\/j.addr.2023.114968_b0350","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.immuni.2019.12.003","article-title":"Microglia, lifestyle stress, and neurodegeneration","volume":"52","author":"Madore","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2023.114968_b0355","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","article-title":"Single-cell transcriptomic analysis of Alzheimer\u2019s disease","volume":"570","author":"Mathys","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114968_b0360","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/374647a0","article-title":"Activation of microglial cells by beta-amyloid protein and interferon-gamma","volume":"374","author":"Meda","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114968_b0365","first-page":"792","article-title":"An early and late peak in microglial activation in Alzheimer\u2019s disease trajectory","volume":"140","author":"Fan","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.addr.2023.114968_b0370","doi-asserted-by":"crossref","first-page":"e99360","DOI":"10.15252\/embj.201899360","article-title":"Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria","volume":"38","author":"Cummins","year":"2019","journal-title":"The EMBO journal"},{"key":"10.1016\/j.addr.2023.114968_b0375","article-title":"Defective mitophagy in Alzheimer\u2019s disease","volume":"101191","author":"Pradeepkiran","year":"2020","journal-title":"Ageing Research Reviews"},{"key":"10.1016\/j.addr.2023.114968_b0380","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrm3028","article-title":"Mechanisms of mitophagy","volume":"12","author":"Youle","year":"2011","journal-title":"Nature reviews Molecular cell biology"},{"key":"10.1016\/j.addr.2023.114968_b0385","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.molcel.2016.02.019","article-title":"Mitochondria\u2014judges and executioners of cell death sentences","volume":"61","author":"Bhola","year":"2016","journal-title":"Molecular cell"},{"key":"10.1016\/j.addr.2023.114968_b0390","doi-asserted-by":"crossref","first-page":"957 970","DOI":"10.1016\/j.cmet.2021.02.017","article-title":"Excessive exercise training causes mitochondrial functional impairment and decreases glucose tolerance in healthy volunteers","volume":"33","author":"Flockhart","year":"2021","journal-title":"Cell metabolism"},{"key":"10.1016\/j.addr.2023.114968_b0395","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jalz.2017.01.020","article-title":"Metabolic network failures in Alzheimer's disease: A biochemical road map","volume":"13","author":"Toledo","year":"2017","journal-title":"Alzheimer's & Dementia"},{"key":"10.1016\/j.addr.2023.114968_b0400","doi-asserted-by":"crossref","unstructured":"T. Sasahara, K. Satomura, M. Tada, A. Kakita, M. Hoshi, Alzheimer\u2019s A\u03b2 assembly binds sodium pump and blocks endothelial NOS activity via ROS-PKC pathway, bioRxiv, (2020).","DOI":"10.1101\/2020.12.10.419879"},{"key":"10.1016\/j.addr.2023.114968_b0405","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/antiox8080265","article-title":"Astrocytic oxidative\/nitrosative stress contributes to Parkinson\u2019s disease pathogenesis: The dual role of reactive astrocytes","volume":"8","author":"Rizor","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.addr.2023.114968_b0410","article-title":"KM Mitochondrial function in Alzheimer\u2019s disease: Focus on astrocytes","volume":"10","author":"Lampinen","year":"2017","journal-title":"Astrocyte Physiol. Pathol"},{"key":"10.1016\/j.addr.2023.114968_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16074-2","article-title":"Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer\u2019s disease","volume":"11","author":"Calvo-Rodriguez","year":"2020","journal-title":"Nature communications"},{"key":"10.1016\/j.addr.2023.114968_b0420","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/ijms17091558","article-title":"ER stress-mediated signaling: Action potential and Ca2+ as key players","volume":"17","author":"Bahar","year":"2016","journal-title":"International journal of molecular sciences"},{"key":"10.1016\/j.addr.2023.114968_b0425","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/ph13100294","article-title":"Overcoming barriers for siRNA therapeutics: From bench to bedside","volume":"13","author":"Sajid","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.addr.2023.114968_b0430","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jddst.2018.04.001","article-title":"siRNA delivery for treatment of degenerative diseases, new hopes and challenges","volume":"45","author":"Zahir-Jouzdani","year":"2018","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"10.1016\/j.addr.2023.114968_b0435","doi-asserted-by":"crossref","first-page":"eabc7031","DOI":"10.1126\/sciadv.abc7031","article-title":"Blood-brain barrier\u2013penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy","volume":"6","author":"Zhou","year":"2020","journal-title":"Science advances"},{"key":"10.1016\/j.addr.2023.114968_b0440","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1038\/mtna.2015.15","article-title":"Intraventricular delivery of siRNA nanoparticles to the central nervous system","volume":"4","author":"Shyam","year":"2015","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"10.1016\/j.addr.2023.114968_b0445","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3109\/00207454.2013.877014","article-title":"Intracranial injection of PEG-PEI\/ROCK II-siRNA improves cognitive impairment in a mouse model of Alzheimer's disease","volume":"124","author":"Wen","year":"2014","journal-title":"International Journal of Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0450","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.colsurfb.2017.01.031","article-title":"Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer\u2019s therapy","volume":"152","author":"Rassu","year":"2017","journal-title":"Colloids and Surfaces B: Biointerfaces"},{"key":"10.1016\/j.addr.2023.114968_b0455","doi-asserted-by":"crossref","first-page":"2203182","DOI":"10.1002\/smll.202203182","article-title":"Intranasal delivery of BACE1 siRNA and rapamycin by dual targets modified nanoparticles for alzheimer's disease therapy","volume":"18","author":"Yang","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.addr.2023.114968_b0460","doi-asserted-by":"crossref","first-page":"e12782","DOI":"10.1111\/nan.12782","article-title":"Dysfunction of the blood\u2013brain barrier in Alzheimer's disease: Evidence from human studies","volume":"48","author":"Kurz","year":"2022","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1016\/j.addr.2023.114968_b0465","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3389\/fneur.2020.594672","article-title":"Pathophysiology of blood\u2013brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and recovery","volume":"11","author":"Bernardo-Castro","year":"2020","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/j.addr.2023.114968_b0470","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s44161-021-00014-4","article-title":"Blood\u2013brain barrier link to human cognitive impairment and Alzheimer\u2019s disease","volume":"1","author":"Barisano","year":"2022","journal-title":"Nature cardiovascular research"},{"key":"10.1016\/j.addr.2023.114968_b0475","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/biomedicines10040742","article-title":"Addressing blood-brain barrier impairment in alzheimer\u2019s disease","volume":"10","author":"Sharma","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2023.114968_b0480","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/156720507780362245","article-title":"Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease","volume":"4","author":"Deane","year":"2007","journal-title":"Current Alzheimer Research"},{"key":"10.1016\/j.addr.2023.114968_b0485","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-180098","article-title":"Role of blood-brain barrier in Alzheimer\u2019s disease","volume":"63","author":"Cai","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/j.addr.2023.114968_b0490","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2016.07.007","article-title":"The blood-brain barrier in Alzheimer's disease","volume":"107","author":"Zenaro","year":"2017","journal-title":"Neurobiology of disease"},{"key":"10.1016\/j.addr.2023.114968_b0495","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.actbio.2016.11.029","article-title":"A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer\u2019s disease mice","volume":"49","author":"Zheng","year":"2017","journal-title":"Acta Biomaterialia"},{"key":"10.1016\/j.addr.2023.114968_b0500","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2018.04.034","article-title":"Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease","volume":"279","author":"Wang","year":"2018","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2023.114968_b0505","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.apsb.2018.12.010","article-title":"Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer\u05f3s disease","volume":"9","author":"Guo","year":"2019","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.addr.2023.114968_b0510","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.biomaterials.2014.10.068","article-title":"Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease","volume":"38","author":"Park","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.114968_b0515","doi-asserted-by":"crossref","first-page":"1909999","DOI":"10.1002\/adfm.201909999","article-title":"Endo\/lysosome-escapable delivery depot for improving BBB transcytosis and neuron targeted therapy of alzheimer's disease","volume":"30","author":"Cai","year":"2020","journal-title":"Advanced Functional Materials"},{"key":"10.1016\/j.addr.2023.114968_b0520","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.11.060","article-title":"Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice","volume":"80","author":"Liu","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.114968_b0525","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature10154","article-title":"Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation","volume":"475","author":"Sievers","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114968_b0530","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2016.03.007","article-title":"A designed recombinant fusion protein for targeted delivery of siRNA to the mouse brain","volume":"228","author":"Haroon","year":"2016","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2023.114968_b0535","doi-asserted-by":"crossref","first-page":"eabc7031","DOI":"10.1126\/sciadv.abc7031","article-title":"Blood-brain barrier\u2013penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy","volume":"6","author":"Zhou","year":"2020","journal-title":"Science Advances"},{"key":"10.1016\/j.addr.2023.114968_b0540","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1002\/anie.201914751","article-title":"Systemic brain delivery of antisense oligonucleotides across the blood\u2013brain barrier with a glucose-coated polymeric nanocarrier","volume":"59","author":"Min","year":"2020","journal-title":"Angewandte Chemie International Edition"},{"key":"10.1016\/j.addr.2023.114968_b0545","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/10717544.2020.1775724","article-title":"Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer\u2019s","volume":"27","author":"Lopez-Barbosa","year":"2020","journal-title":"Drug Delivery"},{"key":"10.1016\/j.addr.2023.114968_b0550","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fncel.2018.00313","article-title":"Effective knockdown of gene expression in primary microglia With siRNA and magnetic nanoparticles without cell death or inflammation","volume":"12","author":"Carrillo-Jimenez","year":"2018","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0555","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.biomaterials.2012.10.013","article-title":"Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases","volume":"34","author":"Malhotra","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.114968_b0560","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/iub.2330","article-title":"Brain-targeted co-delivery of \u03b2-amyloid converting enzyme 1 shRNA and epigallocatechin-3-gallate by multifunctional nanocarriers for Alzheimer's disease treatment","volume":"72","author":"Lv","year":"2020","journal-title":"IUBMB Life"},{"key":"10.1016\/j.addr.2023.114968_b0565","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2217\/clp.14.33","article-title":"Potential of nanoliposomes for the therapy and\/or diagnosis of Alzheimer\u2019s disease: Recent progress","volume":"9","author":"Antimisiaris","year":"2014","journal-title":"Clinical lipidology"},{"key":"10.1016\/j.addr.2023.114968_b0570","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2014.04.050","article-title":"Multifunctional nanoliposomes with curcumin\u2013lipid derivative and brain targeting functionality with potential applications for Alzheimer disease","volume":"80","author":"Mourtas","year":"2014","journal-title":"European journal of medicinal chemistry"},{"key":"10.1016\/j.addr.2023.114968_b0575","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fnsyn.2020.00020","article-title":"Nanoliposomes as a therapeutic tool for Alzheimer\u2019s disease","volume":"12","author":"Ord\u00f3\u00f1ez-Guti\u00e9rrez","year":"2020","journal-title":"Frontiers in Synaptic Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0580","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.2147\/IJN.S183117","article-title":"Liposome delivery systems for the treatment of Alzheimer\u2019s disease","volume":"13","author":"Ross","year":"2018","journal-title":"International journal of nanomedicine"},{"key":"10.1016\/j.addr.2023.114968_b0585","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jconrel.2017.05.013","article-title":"Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease","volume":"258","author":"Mancini","year":"2017","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2023.114968_b0590","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.2147\/IJN.S239608","article-title":"Transferrin-modified osthole pegylated liposomes travel the blood-brain barrier and mitigate Alzheimer\u2019s disease-related pathology in APP\/PS-1 mice","volume":"15","author":"Kong","year":"2020","journal-title":"International Journal of Nanomedicine"},{"key":"10.1016\/j.addr.2023.114968_b0595","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.biomaterials.2010.10.027","article-title":"Curcumin-decorated nanoliposomes with very high affinity for amyloid-\u03b21-42 peptide","volume":"32","author":"Mourtas","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.114968_b0600","first-page":"712","article-title":"Curcumin-conjugated nanoliposomes with high affinity for A\u03b2 deposits: Possible applications to Alzheimer disease, nanomedicine: Nanotechnology","volume":"9","author":"Lazar","year":"2013","journal-title":"Biology and Medicine"},{"key":"10.1016\/j.addr.2023.114968_b0605","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1021\/cr500542t","article-title":"Surface-engineered dendrimers in gene delivery","volume":"115","author":"Yang","year":"2015","journal-title":"Chemical reviews"},{"key":"10.1016\/j.addr.2023.114968_b0610","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/pharmaceutics10040190","article-title":"The delivery challenge in neurodegenerative disorders: The nanoparticles role in Alzheimer\u2019s disease therapeutics and diagnostics","volume":"10","author":"De la Torre","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.114968_b0615","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1016\/j.biomaterials.2009.08.049","article-title":"Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer","volume":"30","author":"Ke","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.114968_b0620","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1096\/fj.06-7380com","article-title":"Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer","volume":"21","author":"Huang","year":"2007","journal-title":"The FASEB journal"},{"key":"10.1016\/j.addr.2023.114968_b0625","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jconrel.2020.10.064","article-title":"Brain gene delivery using histidine and arginine-modified dendrimers for ischemic stroke therapy","volume":"330","author":"Lee","year":"2021","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2023.114968_b0630","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jconrel.2014.12.042","article-title":"In vivo delivery of siRNA to the brain by carbosilane dendrimer","volume":"200","author":"Serram\u00eda","year":"2015","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2023.114968_b0635","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejps.2015.06.024","article-title":"Synthesis and characterization of a PAMAM dendrimer nanocarrier functionalized by SRL peptide for targeted gene delivery to the brain","volume":"78","author":"Zarebkohan","year":"2015","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.addr.2023.114968_b0640","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1021\/mp2005627","article-title":"Phosphorus dendrimers affect Alzheimer\u2019s (A\u03b21\u201328) peptide and MAP-Tau protein aggregation","volume":"9","author":"Wasiak","year":"2012","journal-title":"Molecular pharmaceutics"},{"key":"10.1016\/j.addr.2023.114968_b0645","doi-asserted-by":"crossref","unstructured":"L. F\u00fcl\u00f6p, I.M. M\u00e1ndity, G. Juh\u00e1sz, V. Szegedi, A. Het\u00e9nyi, E. W\u00e9ber, Z. Bozs\u00f3, D. Simon, M. Benk\u0151, Z. Kir\u00e1ly, A foldamer-dendrimer conjugate neutralizes synaptotoxic \u03b2-amyloid oligomers, (2012).","DOI":"10.1371\/journal.pone.0039485"},{"key":"10.1016\/j.addr.2023.114968_b0650","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1021\/bm400948z","article-title":"Effect of poly (propylene imine) glycodendrimers on \u03b2-amyloid aggregation in vitro and in APP\/PS1 transgenic mice, as a model of brain amyloid deposition and Alzheimer\u2019s disease","volume":"14","author":"Klementieva","year":"2013","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2023.114968_b0655","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/pharmaceutics12111125","article-title":"Recent advances on ultrasound contrast agents for blood-brain barrier opening with focused ultrasound","volume":"12","author":"Dauba","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.114968_b0660","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2019.07.023","article-title":"Safety and efficacy of focused ultrasound induced blood-brain barrier opening, an integrative review of animal and human studies","volume":"309","author":"Meng","year":"2019","journal-title":"Journal of controlled release"},{"key":"10.1016\/j.addr.2023.114968_b0665","article-title":"Focused ultrasound assisted nanoplexes for siRNA delivery","author":"Bosch","year":"2022","journal-title":"It\u00e4-Suomen yliopisto"},{"key":"10.1016\/j.addr.2023.114968_b0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-021-00269-8","article-title":"Extensive frontal focused ultrasound mediated blood\u2013brain barrier opening for the treatment of Alzheimer\u2019s disease: A proof-of-concept study","volume":"10","author":"Park","year":"2021","journal-title":"Translational neurodegeneration"},{"key":"10.1016\/j.addr.2023.114968_b0675","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1016\/j.ultrasmedbio.2021.06.005","article-title":"Advances in biological application of and research on low-frequency ultrasound","volume":"47","author":"Mei","year":"2021","journal-title":"Ultrasound in Medicine & Biology"},{"key":"10.1016\/j.addr.2023.114968_b0680","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.omtn.2021.02.032","article-title":"Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro","volume":"24","author":"Guyon","year":"2021","journal-title":"Molecular Therapy-Nucleic Acids"},{"key":"10.1016\/j.addr.2023.114968_b0685","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cell.2016.12.044","article-title":"ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A\u03b2 secretion","volume":"168","author":"Huang","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.114968_b0690","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/mt.2013.118","article-title":"Acat1 knockdown gene therapy decreases amyloid-\u03b2 in a mouse model of Alzheimer's disease","volume":"21","author":"Murphy","year":"2013","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.addr.2023.114968_b0695","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neurobiolaging.2021.02.001","article-title":"Altered sphingolipid function in Alzheimer's disease; A gene regulatory network approach","volume":"102","author":"Giovagnoni","year":"2021","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.addr.2023.114968_b0700","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/mp.2012.15","article-title":"High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease","volume":"17","author":"Pottier","year":"2012","journal-title":"Molecular psychiatry"},{"key":"10.1016\/j.addr.2023.114968_b0705","doi-asserted-by":"crossref","first-page":"135953","DOI":"10.1016\/j.neulet.2021.135953","article-title":"Aberrant expression of miR-148a-3p in Alzheimer\u2019s disease and its protective role against amyloid-\u03b2 induced neurotoxicity","volume":"756","author":"Zhang","year":"2021","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.addr.2023.114968_b0710","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.ymthe.2021.02.008","article-title":"circTulp4 functions in Alzheimer\u2019s disease pathogenesis by regulating its parental gene, Tulp4","volume":"29","author":"Ma","year":"2021","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.addr.2023.114968_b0715","doi-asserted-by":"crossref","first-page":"135542","DOI":"10.1016\/j.neulet.2020.135542","article-title":"MicroRNA-20b-5p aggravates neuronal apoptosis induced by \u03b2-Amyloid via down-regulation of Ras homolog family member C in Alzheimer\u2019s disease","volume":"742","author":"Tian","year":"2021","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.addr.2023.114968_b0720","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.omtn.2021.04.008","article-title":"Rheb-mTOR activation rescues A\u03b2-induced cognitive impairment and memory function by restoring miR-146 activity in glial cells","volume":"24","author":"De","year":"2021","journal-title":"Molecular Therapy-Nucleic Acids"},{"key":"10.1016\/j.addr.2023.114968_b0725","doi-asserted-by":"crossref","first-page":"14820","DOI":"10.1523\/JNEUROSCI.3883-11.2011","article-title":"MicroRNA-137\/181c regulates serine palmitoyltransferase and in turn amyloid \u03b2, novel targets in sporadic Alzheimer's disease","volume":"31","author":"Geekiyanage","year":"2011","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep30953","article-title":"microRNA-132\/212 deficiency enhances A\u03b2 production and senile plaque deposition in Alzheimer\u2019s disease triple transgenic mice","volume":"6","author":"Hernandez-Rapp","year":"2016","journal-title":"Scientific reports"},{"key":"10.1016\/j.addr.2023.114968_b0735","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1089\/dna.2017.4012","article-title":"Long noncoding RNA EBF3-AS promotes neuron apoptosis in Alzheimer's disease","volume":"37","author":"Gu","year":"2018","journal-title":"DNA and cell biology"},{"key":"10.1016\/j.addr.2023.114968_b0740","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/09168451.2018.1562874","article-title":"LncRNA17A regulates autophagy and apoptosis of SH-SY5Y cell line as an in vitro model for Alzheimer\u2019s disease","volume":"83","author":"Wang","year":"2019","journal-title":"Bioscience, biotechnology, and biochemistry"},{"key":"10.1016\/j.addr.2023.114968_b0745","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/WNR.0000000000001057","article-title":"Identification of the biological affection of long noncoding RNA BC200 in Alzheimer\u2019s disease","volume":"29","author":"Li","year":"2018","journal-title":"Neuroreport"},{"key":"10.1016\/j.addr.2023.114968_b0750","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.omtn.2021.02.032","article-title":"Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro","volume":"24","author":"Guyon","year":"2021","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"10.1016\/j.addr.2023.114968_b0755","doi-asserted-by":"crossref","first-page":"31512","DOI":"10.1074\/jbc.M300169200","article-title":"Antagonistic effects of \u03b2-site amyloid precursor protein-cleaving enzymes 1 and 2 on \u03b2-amyloid peptide production in cells","volume":"278","author":"Basi","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.addr.2023.114968_b0760","article-title":"Knockdown of BACE1-AS nonprotein-coding transcript modulates beta-amyloid-related hippocampal neurogenesis","volume":"2011","author":"Modarresi","year":"2011","journal-title":"International Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.addr.2023.114968_b0765","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1038\/mtna.2015.15","article-title":"Intraventricular delivery of siRNA nanoparticles to the central nervous system","volume":"4","author":"Shyam","year":"2015","journal-title":"Molecular Therapy-Nucleic Acids"},{"key":"10.1016\/j.addr.2023.114968_b0770","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1582-4934.2010.01038.x","article-title":"Gene therapy in Alzheimer\u2019s disease\u2013potential for disease modification","volume":"14","author":"Nilsson","year":"2010","journal-title":"Journal of cellular and molecular medicine"},{"key":"10.1016\/j.addr.2023.114968_b0775","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1074\/jbc.RA120.012542","article-title":"Knock-in rats with homozygous PSEN1L435F alzheimer mutation are viable and show selective \u03b3-secretase activity loss causing low A\u03b240\/42 and high A\u03b243: Loss of \u03b3-secretase activity in presenilin-1 L435F KI rat","volume":"295","author":"Tambini","year":"2020","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.addr.2023.114968_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2022.03.011","article-title":"ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease","author":"Li","year":"2022","journal-title":"Neurobiology of aging"},{"key":"10.1016\/j.addr.2023.114968_b0785","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neulet.2006.06.072","article-title":"Chinese Presenilin-1 V97L mutation enhanced A\u03b242 levels in SH-SY5Y neuroblastoma cells","volume":"406","author":"Fang","year":"2006","journal-title":"Neuroscience letters"},{"key":"10.1016\/j.addr.2023.114968_b0790","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1074\/jbc.RA120.012542","article-title":"Knock-in rats with homozygous PSEN1 Alzheimer mutation are viable and show selective \u03b3-secretase activity loss causing low A\u03b240\/42 and high A\u03b243","volume":"295","author":"Tambini","year":"2020","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.addr.2023.114968_b0795","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.scr.2016.08.002","article-title":"Generation of a gene-corrected isogenic control cell line from an alzheimer's disease patient iPSC line carrying a A79V mutation in PSEN1","volume":"17","author":"Pires","year":"2016","journal-title":"Stem cell research"},{"issue":"193","key":"10.1016\/j.addr.2023.114968_b0800","first-page":"e191-193","article-title":"Very early\u2013onset sporadic alzheimer's disease with a de novo mutation in the PSEN1 gene","volume":"53","author":"Lou","year":"2017","journal-title":"Neurobiology of aging"},{"key":"10.1016\/j.addr.2023.114968_b0805","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.4049\/jimmunol.1701446","article-title":"Presenilin 1 regulates NF-\u03baB activation via association with breakpoint cluster region and casein kinase II","volume":"201","author":"Tanaka","year":"2018","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.addr.2023.114968_b0810","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/mp.2012.15","article-title":"High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease","volume":"17","author":"Pottier","year":"2012","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.addr.2023.114968_b0815","doi-asserted-by":"crossref","first-page":"17967","DOI":"10.1073\/pnas.0605461103","article-title":"LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease","volume":"103","author":"Majercak","year":"2006","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.addr.2023.114968_b0820","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neurobiolaging.2021.02.001","article-title":"Altered sphingolipid function in Alzheimer's disease; A gene regulatory network approach","volume":"102","author":"Giovagnoni","year":"2021","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.addr.2023.114968_b0825","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","article-title":"Microglia in alzheimer\u2019s disease","volume":"217","author":"Hansen","year":"2018","journal-title":"Journal of Cell Biology"},{"issue":"2013","key":"10.1016\/j.addr.2023.114968_b0830","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2023.114968_b0835","doi-asserted-by":"crossref","first-page":"13320","DOI":"10.1523\/JNEUROSCI.1224-13.2013","article-title":"CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing","volume":"33","author":"Malik","year":"2013","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0840","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.neuron.2013.04.014","article-title":"Alzheimer\u2019s disease risk gene CD33 inhibits microglial uptake of amyloid beta","volume":"78","author":"Griciuc","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.addr.2023.114968_b0845","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nn.3435","article-title":"CD33 Alzheimer's disease locus: Altered monocyte function and amyloid biology","volume":"16","author":"Bradshaw","year":"2013","journal-title":"Nature neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0850","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1093\/hmg\/ddv092","article-title":"Genetics of CD33 in alzheimer's disease and acute myeloid leukemia","volume":"24","author":"Malik","year":"2015","journal-title":"Human molecular genetics"},{"key":"10.1016\/j.addr.2023.114968_b0855","doi-asserted-by":"crossref","first-page":"17967","DOI":"10.1073\/pnas.0605461103","article-title":"LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset alzheimer's disease","volume":"103","author":"Majercak","year":"2006","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.addr.2023.114968_b0860","doi-asserted-by":"crossref","first-page":"30953","DOI":"10.1038\/srep30953","article-title":"microRNA-132\/212 deficiency enhances A\u03b2 production and senile plaque deposition in alzheimer\u2019s disease triple transgenic mice","volume":"6","author":"Hernandez-Rapp","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.addr.2023.114968_b0865","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.bbadis.2013.09.008","article-title":"RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity, biochimica et biophysica acta (BBA) -","volume":"1832","author":"Manczak","year":"2013","journal-title":"Molecular Basis of Disease"},{"key":"10.1016\/j.addr.2023.114968_b0870","article-title":"RNA interference mediated treatment of Alzheimer's disease using short interfering RNA","author":"McSwiggen","year":"2003","journal-title":"Google Patents"},{"key":"10.1016\/j.addr.2023.114968_b0875","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1074\/jbc.M309219200","article-title":"BACE1 suppression by RNA interference in primary cortical neurons","volume":"279","author":"Kao","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.addr.2023.114968_b0880","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/emmm.201101084","article-title":"\u03b2-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment","volume":"4","author":"Cai","year":"2012","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.addr.2023.114968_b0885","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1166\/jnsne.2013.1084","article-title":"BACE1 silencing using siRNA shows immediate, dynamic changes in spontaneous electrical activity of cultured neurons","volume":"2","author":"Sridharan","year":"2013","journal-title":"Journal of Neuroscience and Neuroengineering"},{"key":"10.1016\/j.addr.2023.114968_b0890","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1523\/JNEUROSCI.2766-05.2005","article-title":"BACE1, a major determinant of selective vulnerability of the brain to amyloid-\u03b2 amyloidogenesis, is essential for cognitive, emotional, and synaptic functions","volume":"25","author":"Laird","year":"2005","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0895","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tins.2016.01.003","article-title":"BACE1 physiological functions may limit its use as therapeutic target for Alzheimer's disease","volume":"39","author":"Bar\u00e3o","year":"2016","journal-title":"Trends in neurosciences"},{"key":"10.1016\/j.addr.2023.114968_b0900","doi-asserted-by":"crossref","unstructured":"X. Xian, T. Pohlkamp, M.S. Durakoglugil, C.H. Wong, J.K. Beck, C. Lane-Donovan, F. Plattner, J. Herz, Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer\u2019s disease, eLife, 7 (2018) e40048.","DOI":"10.7554\/eLife.40048"},{"key":"10.1016\/j.addr.2023.114968_b0905","unstructured":"C. Ferguson, Modulating ApoE with Tissue Specific siRNAs in Alzheimer\u2019s Disease, GSBS Dissertations and Theses, (2021)."},{"key":"10.1016\/j.addr.2023.114968_b0910","doi-asserted-by":"crossref","unstructured":"R.J. Kandimalla, W.Y. Wani, B. Bk, K.D. Gill, siRNA against presenilin 1 (PS1) down regulates amyloid b42 production in IMR-32 cells, (2012) 9.","DOI":"10.1186\/1423-0127-19-2"},{"key":"10.1016\/j.addr.2023.114968_b0915","first-page":"1613618","article-title":"Down-regulation amyloid beta-protein 42 production by interfering with transcript of presenilin 1 gene with siRNA","volume":"25","author":"Luo","year":"2016","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.addr.2023.114968_b0920","doi-asserted-by":"crossref","first-page":"e809218","DOI":"10.4061\/2011\/809218","article-title":"Specific silencing of L392V PSEN1 mutant allele by RNA interference","volume":"2011","author":"Sierant","year":"2011","journal-title":"International Journal of Alzheimer’ s Disease"},{"key":"10.1016\/j.addr.2023.114968_b0925","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.brainres.2012.10.039","article-title":"Investigation of the performance of PEG\u2013PEI\/ROCK-II-siRNA complexes for Alzheimer's disease in vitro","volume":"1490","author":"Liu","year":"2013","journal-title":"Brain Research"},{"key":"10.1016\/j.addr.2023.114968_b0930","doi-asserted-by":"crossref","first-page":"120160","DOI":"10.1016\/j.biomaterials.2020.120160","article-title":"MOF-encapsulated nanozyme enhanced siRNA combo: Control neural stem cell differentiation and ameliorate cognitive impairments in Alzheimer's disease model","volume":"255","author":"Yu","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.114968_b0935","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.smaim.2020.08.001","article-title":"Synergic treatment of Alzheimer\u2019s disease with brain targeted nanoparticles incorporating NgR-siRNA and brain derived neurotrophic factor","volume":"1","author":"Wang","year":"2020","journal-title":"Smart Materials in Medicine"},{"key":"10.1016\/j.addr.2023.114968_b0940","unstructured":"ALZ.org, https:\/\/www.alz.org\/alzheimers-dementia\/treatments\/medications-for-memory, 2021."},{"key":"10.1016\/j.addr.2023.114968_b0945","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-021-00843-2","article-title":"A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer\u2019s disease","volume":"13","author":"Prins","year":"2021","journal-title":"Alzheimer's research & therapy"},{"key":"10.1016\/j.addr.2023.114968_b0950","unstructured":"E.P. Inc, Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease (REVERSE-SD https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03402659., 2021."},{"key":"10.1016\/j.addr.2023.114968_b0955","unstructured":"ClinicalTrials.gov, Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02534480., 2021."},{"key":"10.1016\/j.addr.2023.114968_b0960","unstructured":"ClinicalTrials.gov, Gene Therapy for APOE4 Homozygote of Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03634007, 2021."},{"key":"10.1016\/j.addr.2023.114968_b0965","unstructured":"ClinicalTrials.gov, Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03634007, 2019."},{"key":"10.1016\/j.addr.2023.114968_b0970","unstructured":"ClinicalTrials.gov, The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00381381, 2012."},{"key":"10.1016\/j.addr.2023.114968_b0975","unstructured":"ClinicalTrials.gov, The Study of microRNA 107 (miRNA 107) and Beta-amyloid Precursor Protein-cleaving Enzyme 1 (BACE1) Messenger Ribonucleic Acid (mRNA) Gene Expression in Cerebrospinal Fluid and Peripheral Blood of Alzheimer's Disease, 2014."},{"key":"10.1016\/j.addr.2023.114968_b0980","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.13m08812","article-title":"The feasibility of utilizing plasma MiRNA107 and BACE1 messenger RNA gene expression for clinical diagnosis of amnestic mild cognitive impairment","volume":"76","author":"Wang","year":"2015","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.addr.2023.114968_b0985","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fnagi.2016.00112","article-title":"Abnormal changes of brain cortical anatomy and the association with plasma MicroRNA107 level in amnestic mild cognitive impairment","volume":"8","author":"Wang","year":"2016","journal-title":"Frontiers in aging neuroscience"},{"key":"10.1016\/j.addr.2023.114968_b0990","unstructured":"ClinicalTrials.gov, Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04693520, 2021."},{"key":"10.1016\/j.addr.2023.114968_b0995","unstructured":"ClinicalTrials.gov, Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00348140, 2017."},{"key":"10.1016\/j.addr.2023.114968_b1000","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156720511796391935","article-title":"Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: Two phase 3 studies","volume":"8","author":"Harrington","year":"2011","journal-title":"Current Alzheimer Research"},{"key":"10.1016\/j.addr.2023.114968_b1005","unstructured":"ClinicalTrials.gov, Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheime\u0155s Disease (SUN-AK) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00951834, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1010","unstructured":"ClinicalTrials.gov, S-Equol in Alzheimer's Disease (SEAD) Trial (SEAD)https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02142777, 2016."},{"key":"10.1016\/j.addr.2023.114968_b1015","unstructured":"ClinicalTrials.gov, Trial of Oxaloacetate in Alzheimer's Disease (TOAD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02593318, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1020","unstructured":"ClinicalTrials.gov, Imaging of Brain Structural\/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers. (Protocol Z) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03816228, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archneur.62.6.953","article-title":"Sex, apolipoprotein E \u03b54 status, and hippocampal volume in mild cognitive impairment","volume":"62","author":"Fleisher","year":"2005","journal-title":"Archives of neurology"},{"key":"10.1016\/j.addr.2023.114968_b1030","unstructured":"ClinicalTrials.gov, OmegAD (Omega-3 and Alzheimer's Disease) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00211159, 2017."},{"key":"10.1016\/j.addr.2023.114968_b1035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3233\/JAD-170359","article-title":"Does fatty acid composition in subcutaneous adipose tissue differ between patients with alzheimer\u2019s disease and cohabiting proxies?","volume":"61","author":"Faxen-Irving","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/j.addr.2023.114968_b1040","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3945\/ajcn.117.155648","article-title":"DHA-rich n\u20133 fatty acid supplementation decreases DNA methylation in blood leukocytes: The OmegAD study","volume":"106","author":"Karimi","year":"2017","journal-title":"The American journal of clinical nutrition"},{"key":"10.1016\/j.addr.2023.114968_b1045","unstructured":"ClinicalTrials.gov, The Impact of Lorazepam on Cognition in APOE e4 Carriers https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00586430, 2008."},{"key":"10.1016\/j.addr.2023.114968_b1050","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.08m04593","article-title":"Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-\u03b54 carriers","volume":"70","author":"Stonnington","year":"2009","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.addr.2023.114968_b1055","unstructured":"ClinicalTrials.gov, Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease (BIOMAGE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01095744, 2012."},{"key":"10.1016\/j.addr.2023.114968_b1060","unstructured":"ClinicalTrials.gov, n-3 PUFA for Vascular Cognitive Aging https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01953705, 2020."},{"key":"10.1016\/j.addr.2023.114968_b1065","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/nu11040735","article-title":"Randomized trial of marine n-3 polyunsaturated fatty acids for the prevention of cerebral small vessel disease and inflammation in aging (PUFA Trial): Rationale, design and baseline results","volume":"11","author":"Bowman","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.addr.2023.114968_b1070","unstructured":"ClinicalTrials.gov, A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02565511?term=CAD106&cond=Alzheimer+Disease&draw=2&rank=1, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1075","first-page":"7","volume":"F1000Research","author":"Weller","year":"2018","journal-title":"Current understanding of Alzheimer\u2019s disease diagnosis and treatment"},{"key":"10.1016\/j.addr.2023.114968_b1080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active A\u03b2 immunotherapy with CAD106 in mild Alzheimer\u2019s disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimer's research & therapy"},{"key":"10.1016\/j.addr.2023.114968_b1085","unstructured":"ClinicalTrials.gov, A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS2) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03131453?term=CNP520&cond=Alzheimer+Disease&draw=2&rank=1, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1090","unstructured":"ClinicalTrials.gov, AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04468659?term=BAN2401&cond=Alzheimer+Disease&draw=2&rank=4, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1095","unstructured":"ClinicalTrials.gov, An Open-Label Crenezumab Study in Participants With Alzheimer's Disease (CREAD OLE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03491150?term=Crenezumab&cond=Alzheimer+Disease&draw=2&rank=1, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1100","unstructured":"ClinicalTrials.gov, A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities (EVOLVE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03639987?term=Aducanumab%2C.+amyloid&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1105","unstructured":"clinicalTrials.gov, Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02551809?term=Amyloid%2C+UB-311&cond=Alzheimer+Disease&draw=2&rank=3 2021."},{"key":"10.1016\/j.addr.2023.114968_b1110","unstructured":"ClinicalTrials.gov, A Study of Gantenerumab in Participants With Mild Alzheimer Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02051608?term=Gantenerumab%2C+Amyloid&cond=Alzheimer+Disease&draw=2&rank=4 2021."},{"key":"10.1016\/j.addr.2023.114968_b1115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: A PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimer's research & therapy"},{"key":"10.1016\/j.addr.2023.114968_b1120","unstructured":"ClinicalTrials.gov, Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00905372?term=Solanezumab%2C+Amyloid&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1125","unstructured":"ClinicalTrials.gov, Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03522129?term=CT1812%2C+Amyloid&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1130","unstructured":"ClinicalTrials.gov, Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers (drainAD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03417986?term=Thiethylperazine&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1135","unstructured":"ClinicalTrials.gov, Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03363269?term=ID1201&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1140","unstructured":"C. Tirals, Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03008161, 2019."},{"key":"10.1016\/j.addr.2023.114968_b1145","unstructured":"ClinicalTrials.gov, Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03819699?term=Lu+AF20513%2C+Amyloid&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1150","unstructured":"ClinicalTrials.gov, Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03461276?term=ABvac40&cond=Alzheimer+Disease&draw=2&rank=2 2021."},{"key":"10.1016\/j.addr.2023.114968_b1155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b2 40 vaccine (ABvac40) in patients with Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimer's research & therapy"},{"key":"10.1016\/j.addr.2023.114968_b1160","unstructured":"ClinicalTrials.gov, A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00945672?term=Ponezumab%2C+amyloid&cond=Alzheimer+Disease&draw=2&rank=2 2021."},{"key":"10.1016\/j.addr.2023.114968_b1165","unstructured":"ClinicalTrials.gov, Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01227564?term=ACC-001%2C+amyloid&cond=Alzheimer+Disease&draw=2&rank=2 2021."},{"key":"10.1016\/j.addr.2023.114968_b1170","first-page":"75","article-title":"Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early alzheimer's disease: Amyloid imaging positron emission tomography and safety results from a phase 2 study","volume":"3","author":"Van Dyck","year":"2016","journal-title":"The journal of prevention of Alzheimer's disease"},{"key":"10.1016\/j.addr.2023.114968_b1175","unstructured":"ClinicalTrials.gov, A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03093519?term=KHK6640&cond=Alzheimer+Disease&draw=2&rank=3 2021."},{"key":"10.1016\/j.addr.2023.114968_b1180","unstructured":"ClinicalTrials.gov, Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01424436?term=GSK933776&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1185","doi-asserted-by":"crossref","first-page":"e0098153","DOI":"10.1371\/journal.pone.0098153","article-title":"First administration of the Fc-attenuated anti-\u03b2 amyloid antibody GSK933776 to patients with mild Alzheimer\u2019s disease: A randomized, placebo-controlled study","volume":"10","author":"Andreasen","year":"2015","journal-title":"PloS one"},{"key":"10.1016\/j.addr.2023.114968_b1190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt249","article-title":"Modulation of \u03b2-amyloid by a single dose of GSK933776 in patients with mild Alzheimer\u2019s disease: A phase I study","volume":"6","author":"Leyhe","year":"2014","journal-title":"Alzheimer's research & therapy"},{"key":"10.1016\/j.addr.2023.114968_b1195","unstructured":"ClinicalTrials.gov, Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00965588?term=UB-311+%2C+amyloid&cond=Alzheimer+Disease&draw=2&rank=2 2021."},{"key":"10.1016\/j.addr.2023.114968_b1200","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.vaccine.2007.01.031","article-title":"Site-specific UBITh\u00ae amyloid-\u03b2 vaccine for immunotherapy of Alzheimer's disease","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.114968_b1205","unstructured":"ClinicalTrials.gov, Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03113812?term=ABvac40&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-020-00614-5","article-title":"Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer\u2019s disease spectrum patients: A randomized, double-blind, placebo-controlled study and a two-period extension study","volume":"12","author":"Novak","year":"2020","journal-title":"Alzheimer's research & therapy"},{"key":"10.1016\/j.addr.2023.114968_b1215","series-title":"Elenbecestat trials in early alzheimer disease terminated for poor","author":"Bigica","year":"2019"},{"key":"10.1016\/j.addr.2023.114968_b1220","article-title":"Phase 3 trials of elenbecestat in early alzheimer\u2019s stopped for lack of benefit","author":"PhD","year":"2019","journal-title":"Eisai and Biogen Say"},{"key":"10.1016\/j.addr.2023.114968_b1225","unstructured":"ClinicalTrials.gov, An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) (EPOCH) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01739348, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-019-0520-1","article-title":"Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer\u2019s disease","volume":"11","author":"Egan","year":"2019","journal-title":"Alzheimer's research & therapy"},{"key":"10.1016\/j.addr.2023.114968_b1235","unstructured":"clinicalTrials.gov, A Study of Semagacestat for Alzheimer's Patients (Identity XT) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01035138?term=LY450139&cond=Alzheimer+Disease&draw=2&rank=5 2021."},{"key":"10.1016\/j.addr.2023.114968_b1240","unstructured":"ClinicalTrials.gov, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03186989?term=IONIS-MAPTRx&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1245","unstructured":"ClinicalTrials.gov, A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03375697?term=JNJ-63733657&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1250","unstructured":"ClinicalTrials.gov, A Study of Semorinemab in Patients With Moderate Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03828747 2021."},{"key":"10.1016\/j.addr.2023.114968_b1255","unstructured":"A.I. SA, AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer\u2019s Disease https:\/\/www.globenewswire.com\/news-release\/2019\/02\/20\/1738228\/0\/en\/AC-Immune-Announces-Anti-Tau-Monoclonal-Antibody-Entering-Second-Phase-2-Trial-in-Moderate-Alzheimer-s-Disease.html, 2019."},{"key":"10.1016\/j.addr.2023.114968_b1260","unstructured":"ClinicalTrials.gov, A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02880956?term=ABBV-8E12&cond=Alzheimer+Disease&draw=2&rank=2 2021."},{"key":"10.1016\/j.addr.2023.114968_b1265","unstructured":"A.s. News, ABBV-8E12."},{"key":"10.1016\/j.addr.2023.114968_b1270","doi-asserted-by":"crossref","unstructured":"A. Mullard, Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating, (2020).","DOI":"10.1038\/d41573-020-00217-7"},{"key":"10.1016\/j.addr.2023.114968_b1275","unstructured":"ClinicalTrials.gov, 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (ADAMANT) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02579252?term=AADvac1&cond=Alzheimer+Disease&draw=2&rank=3 2021."},{"key":"10.1016\/j.addr.2023.114968_b1280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt277","article-title":"Identification of structural determinants on tau protein essential for its pathological function: Novel therapeutic target for tau immunotherapy in Alzheimer\u2019s disease","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimer's research & therapy"},{"key":"10.1016\/j.addr.2023.114968_b1285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau\u2013tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimer's research & therapy"},{"key":"10.1016\/j.addr.2023.114968_b1290","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.addr.2023.114968_b1295","unstructured":"ClinicalTrials.gov, Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03352557?term=BIIB-092&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1300","unstructured":"I. Relations, Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer\u2019s Disease https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-announces-topline-results-phase-2-study-gosuranemab-anti, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1305","unstructured":"Alzheimersnewstoday, AAIC21 \u2013 BIIB080 Safely Lowered Tau Levels in Patients in Phase 1 Trial https:\/\/alzheimersnewstoday.com\/2021\/08\/16\/aaic21-biib080-safely-lowered-tau-levels-in-patients-in-phase-1-trial\/ 2021."},{"key":"10.1016\/j.addr.2023.114968_b1310","unstructured":"ClinicalTrials.gov, A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01966666?term=TPI-287&cond=Alzheimer+Disease&draw=2&rank=1 2021."},{"key":"10.1016\/j.addr.2023.114968_b1315","unstructured":"Alzforum, Therapeutics LMTM, Tau aggregation inhibitor (TAI) https:\/\/www.alzforum.org\/therapeutics\/lmtm 2021."},{"key":"10.1016\/j.addr.2023.114968_b1320","unstructured":"ClinicalTrials.gov, Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03446001?term=TRx0237&cond=Alzheimer+Disease&draw=2&rank=5 2021."},{"key":"10.1016\/j.addr.2023.114968_b1325","unstructured":"ClinicalTrials.gov, A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02754830 2021."},{"key":"10.1016\/j.addr.2023.114968_b1330","unstructured":"Alzheimersnewstoday, Zagotenemab (Formerly LY3303560) https:\/\/alzheimersnewstoday.com\/eli-lilly-zagotenemab-ly3303560-alzheimers-tau-antibody\/ 2021."},{"key":"10.1016\/j.addr.2023.114968_b1335","unstructured":"ClinicalTrials.gov, Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN\u00ae in Subjects With Amnestic Mild Cognitive Impairment https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01072812?term=Posiphen&cond=Alzheimer+Disease&draw=2&rank=3 2021."},{"key":"10.1016\/j.addr.2023.114968_b1340","unstructured":"Alzforum, Therapeutics, Posiphen https:\/\/www.alzforum.org\/therapeutics\/posiphen 2021."},{"key":"10.1016\/j.addr.2023.114968_b1345","unstructured":"ClinicalTrials.gov, Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (STEADFAST) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02080364?term=Azeliragon&cond=Alzheimer+Disease&rank=2, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1350","unstructured":"A.s.N. Today, Azeliragon, https:\/\/alzheimersnewstoday.com\/azeliragon\/, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1355","unstructured":"ClinicalTrials.gov, Alzheimer's Disease Acitretin Medication (ADAM)https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01078168?term=Acitretin&cond=Alzheimer+Disease&draw=2&rank=1 2018."},{"key":"10.1016\/j.addr.2023.114968_b1360","unstructured":"ClinicalTrials.gov, Bexarotene Amyloid Treatment for Alzheimer's Disease (BEAT-AD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01782742?term=Bexarotene&cond=Alzheimer+Disease&draw=2&rank=1, 2021."},{"key":"10.1016\/j.addr.2023.114968_b1365","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.2147\/IJN.S106625","article-title":"Lipid nanoparticles for targeted siRNA delivery\u2013going from bench to bedside","volume":"11","author":"Zatsepin","year":"2016","journal-title":"International journal of nanomedicine"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23002831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23002831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:48:06Z","timestamp":1759211286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23002831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":273,"alternative-id":["S0169409X23002831"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.114968","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"siRNA drug delivery across the blood\u2013brain barrier in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.114968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114968"}}